Skip to content
OpenCapital
Get started

Turn Therapeutics Inc. TTRX Q1 2026 Annual earnings

Reported May 11, 2026 · Before market open

Diluted EPS-$0.03Miss by $0.01
EPS estimate-$0.02

Next report

Sep 2, 2026 (in 2 months)
EPS estimate-$0.02

Financials

Q1 2026

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M—
Total equity$6.1M+647%
Total assets$18.6M—

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$262.43M—
Enterprise value$257.22M—

Returns & leverage

See full
Debt / equity1×—
Current ratio2.2×—

Versus estimates

Diluted EPS

Q1 2026-$0.03Miss by $0.01
Q4 2025-$0.09Miss by $0.04Q3 2025-$0.07

Ask the moment Turn Therapeutics Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Turn Therapeutics Inc. report Q1 2026 earnings?
Turn Therapeutics Inc. (TTRX) reported Q1 2026 earnings on May 11, 2026 before market open.
What were Turn Therapeutics Inc.'s Q1 2026 revenue and EPS?
Turn Therapeutics Inc. reported diluted EPS of $-0.03 for Q1 2026.
Did Turn Therapeutics Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.02 by $0.01.
Where can I find Turn Therapeutics Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-054480) and the 10-K periodic report (0001213900-26-037505) directly on SEC EDGAR. The filing index links above go to sec.gov.